(lp0
S'Alseres Pharmaceuticals, Inc. Reports License of Altropane Worldwide Rights ... PR Newswire  - Jul 31, 2012 HOPKINTON, Mass., July 31, 2012 /PRNewswire/ -- Alseres Pharmaceuticals, Inc.  today announced that it has entered into an agreement with Navidea Biopharmaceuticals, Inc.  to license, [123I]-E-IACFT Injection&nbsp;...'
p1
aS'Navidea Divests NAV5001, a Non-Core, Development-Stage Imaging Agent for ... Business Wire  - Apr 27, 2015 DUBLIN, Ohio----Navidea Biopharmaceuticals, Inc. , today announced that it has entered into an agreement with Alseres Pharmaceuticals, Inc. to terminate the sub-license agreement dated July 31, 2012 for research,&nbsp;...'
p2
aS'Boston Life Sciences  Changes its Name to Alseres, Trade Under Symbol &quot;ALSE&quot; StreetInsider.com  - Jun 8, 2007 Boston Life Sciences, Inc.  announced that its proposed name change to Alseres Pharmaceuticals, Inc., was approved by its stockholders at its annual meeting of stockholders.'
p3
aS'Global Radiopharmaceuticals Industry PR Newswire  - Aug 6, 2013 The report profiles 69 companies including many key and niche players such as Actinium Pharmaceuticals, Inc., Advanced Medical Isotope Corporation, Alseres Pharmaceuticals, Inc., Bayer HealthCare Pharmaceuticals, Bracco Diagnostics, Inc., Cardinal&nbsp;...'
p4
aS'Research and Markets: Radiopharmaceuticals Market 2015: Diagnostic ... Business Wire  - Apr 30, 2015 This report analyzes the worldwide markets for Radiopharmaceuticals in US$ Million by the following Segments: Diagnostic Radiopharmaceuticals, and Therapeutic Radiopharmaceuticals.'
p5
aS'Global Central Nervous System  Biomarkers Market 2016 - 2022 - Research ... Business Wire  - Jun 10, 2016 The global CNS biomarkers market is expected to reach up to $6.2 billion by 2022, growing at 10.4% CAGR during 2016-2022. The demand for CNS biomarkers has increased with the development of proteomics, genomics and imaging systems, which are&nbsp;...'
p6
aS'Biotech Stock Directory Update InvestorIdeas.com  - Aug 14, 2014 Alseres Pharmaceuticals, Inc .  Alseres Pharmaceuticals, Inc.  is engaged in the development of therapeutic and diagnostic products primarily for disorders in the central nervous system .'
p7
aS'Agilis Biotherapeutics Names Dr. Mark J. Pykett as President and Chief ... Business Wire  - Sep 10, 2014 Prior to Navidea, from 2004 to 2010, Dr. Pykett served as President and Chief Operating Officer of Alseres Pharmaceuticals, a biotechnology company focused on neurodegenerative and central nervous system disorders, playing a critical role in the ...'
p8
aS'Global Central Nervous System  Biomarkers Market by Country (United ... Thrasher Backer - 20 hours ago The key players in global CNS biomarker market are Abastar MDX Inc, Thermo fisher scientific, Abiant Inc, EKFdiagnostics holdings Inc, Enzo biochem Inc, Acumen pharmaceuticals Inc, Adlyfe Inc, Alseres pharmaceuticals Inc, Apitope international ...'
p9
aS'Global Central Nervous System  Biomarkers Market Research 2015-2020 ... Business Wire  - Sep 9, 2016 The Global Central Nervous System  Biomarkers Market is expected to grow at a CAGR 18% during 2015-2020. The Global CNS Biomarkers Market is growing at a modest rate due to development in imaging system, proteomics &amp; genomics and rise in&nbsp;...'
p10
a.